<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091298</url>
  </required_header>
  <id_info>
    <org_study_id>SBL/BRVTV/Form1/Adlts/PhI/2010</org_study_id>
    <nct_id>NCT01091298</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of Tetravalent Rotavirus Vaccine in Healthy Indian Adult Male Volunteers</brief_title>
  <official_title>Phase I Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Tolerability of a Single Administration (10e6.25 FFU of Each Constituent Serotype Per 0.5 ml) of Live Attenuated Tetravalent (G1-G4) Bovine-human Reassortant Rotavirus Vaccine [BRV-TV] Administered to Healthy Indian Adult Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shantha Biotechnics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shantha Biotechnics Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I study to evaluate the safety and tolerability of the tetravalent rota virus
      vaccine in healthy Indian adult male volunteers administered a single dose of the vaccine at
      the highest possible viral concentration in 0.5 mL of vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity and causality of all Adverse Events following the dose of vaccine/placebo</measure>
    <time_frame>upto 10 days following administration of vaccine/placebo</time_frame>
    <description>The frequency, severity and causality of all solicited and unsolicited adverse events following administration of a single dose of the vaccine as compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The frequency and the percentage change, as compared to baseline, in the protocol defined laboratory parameters following the single dose of Vaccine/placebo</measure>
    <time_frame>Upto 10 days following administration of vaccine/placebo</time_frame>
    <description>The frequency, percentage change, as compared to baseline, and causality of all the defined laboratory parameters following administration of a single dose of the vaccine as compared to placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Rotavirus Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)</intervention_name>
    <description>Single dose (0.5 mL) of the vaccine administered orally</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single dose (0.5 mL) of the placebo administered orally</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Indian adult male volunteers.

          -  No apparent signs or symptoms of ill health.

          -  Properly informed about the study and having signed the informed consent form (ICF).
             In case of the volunteer being unable to read or write, having had the ICF explained
             to them in the presence of a study independent witness and the witness having signed
             the ICF;

          -  Subject available for the entire period of the study and reachable by study staff for
             post-vaccination follow-up.

        Exclusion Criteria:

          -  Known or suspected impairment of immunological function;

          -  Known hypersensitivity to any component of the rotavirus vaccine;

          -  Fever, with axillary temperature ≥38.1oC (≥100.5oF); measured by study staff.

          -  History of chronic diarrhea;

          -  Clinical evidence of active gastrointestinal illness;

          -  Receipt of any intramuscular (IM), oral, or intravenous (IV) corticosteroid treatment
             in the past 30 days

          -  Subjects suspected to be HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV)
             positive from the available clinical history

          -  Prior receipt of a blood transfusion or blood products, including immunoglobulins;

          -  Any subject who cannot be adequately followed for safety;

          -  Any conditions which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives.

          -  Subject unable to maintain diary card
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raman Rao, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shantha Biotechnics Limited</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>TamilNadu</state>
        <zip>632002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <last_update_submitted>June 7, 2011</last_update_submitted>
  <last_update_submitted_qc>June 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Head- Research and Development</name_title>
    <organization>Shantha Biotechnics Limited</organization>
  </responsible_party>
  <keyword>Safety of vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

